Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.
I van OostrumT Alexander Russell-SmithM JakobssonJ Torup ØstbyB HeegPublished in: PharmacoEconomics - open (2021)
InO can likely be considered cost-effective versus SoC under our and the HTA-preferred settings.